Cybin (CYBN) Stock Price, News & Analysis

Company Overview

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $9.11 to $9.67
• 50-Day Range: $9.32 to $12.00
• 52-Week Range: $6.50 to $19.85
• Volume: 392,007 shs
• Average Volume: 190,776 shs
• Market Capitalization: $192.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

CYBN Stock Analysis - Frequently Asked Questions

How have CYBN shares performed this year?

Cybin's stock was trading at $0.41 at the beginning of 2024. Since then, CYBN shares have increased by 2,243.9% and is now trading at $9.61.
View the best growth stocks for 2024 here.

How do I buy shares of Cybin?

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cybin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CYBN
• CUSIP: N/A
• CIK: 1833141
• Web: www.cybin.com
• Phone: (866) 292-4601
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -93.17%
• Return on Assets: -84.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.61
• Quick Ratio: 2.61

Sales & Book Value

• Annual Sales: $680,000.00
• Price / Sales: 282.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 50.58

Miscellaneous

• Outstanding Shares: 19,992,000
• Free Float: 170,213,000
• Market Cap: $192.12 million
• Optionable: Not Optionable
• Beta: 0.39